Form 13-F position report

SPERO THERAPEUTICS INC

Reported by MORGAN STANLEY

Company profile Manager portfolio Source filing
SPRO CUSIP 84833T103 Manager CIK 0000895421
Latest reported change

Reported 72,996 shares, up 22,584 (44.8%) from the prior quarter.

Reported value -21.3%; share count 44.8% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q1 2022
Shares 72,996 Quarter-end amount reported
Reported value $635,000 Fair value at quarter end
Consecutive quarters held 18 Through Q1 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q2 2026 Reduced 914 -3,638 (-79.9%) < 0.01% $2,020 2026-08-13
Q1 2026 Added 4,552 +4,239 (1354.3%) < 0.01% $10,651 2026-05-15
Q4 2025 Reduced 313 -43,065 (-99.3%) < 0.01% $729 2026-02-13
Q3 2025 Added 43,378 +34,157 (370.4%) < 0.01% $81,550 2025-11-14
Q2 2025 Added 9,221 +2,250 (32.3%) < 0.01% $26,741 2025-08-15
Q1 2025 Unchanged 6,971 0 (0.0%) < 0.01% $5,019 2025-05-15
Q4 2024 Unchanged 6,971 0 (0.0%) < 0.01% $7,180 2025-02-14
Q3 2024 Unchanged 6,971 0 (0.0%) < 0.01% $9,341 2024-11-14
Q2 2024 Reduced 6,971 -928 (-11.7%) < 0.01% $9,062 2024-08-14
Q1 2024 Reduced 7,899 -4,136 (-34.4%) < 0.01% $13,586 2024-05-15
Q4 2023 Added 12,035 +3,047 (33.9%) < 0.01% $17,691 2024-02-13
Q3 2023 Reduced 8,988 -542 (-5.7%) < 0.01% $10,875 2023-11-15
Q2 2023 Reduced 9,530 -5,700 (-37.4%) < 0.01% $13,819 2023-08-14
Q1 2023 Reduced 15,230 -1,847 (-10.8%) < 0.01% $22,084 2023-05-15
Q4 2022 Reduced 17,077 -2,177 (-11.3%) < 0.01% $29,543 2023-02-14
Q3 2022 Reduced 19,254 -174,355 (-90.1%) < 0.01% $38,000 2022-11-14
Q2 2022 Added 193,609 +120,613 (165.2%) < 0.01% $143,000 2022-08-15
Q1 2022 Added 72,996 +22,584 (44.8%) < 0.01% $635,000 2022-05-13
Q4 2021 Reduced 50,412 -6,089 (-10.8%) < 0.01% $807,000 2022-02-14
Q3 2021 Reduced 56,501 -13,271 (-19.0%) < 0.01% $1,041,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history
Institutional context

Who else reported the position

108 managers reported SPERO THERAPEUTICS INC for Q1 2022.

Manager Activity Shares Change % of reported 13F Reported value Tenure
Aquilo Capital Management LLC Added 5,281,504 +317,323 6.75% $45,949,000 14 qtrs
BlackRock Inc Reduced 1,794,081 -4,696 < 0.01% $15,609,000 18 qtrs
BVF INC IL Unchanged 1,585,615 0 0.55% $13,795,000 18 qtrs
Atlas Venture Associates IX LLC Unchanged 1,376,968 0 11.02% $11,980,000 18 qtrs
VANGUARD GROUP INC Added 1,373,928 +22,550 < 0.01% $11,953,000 18 qtrs
Atlas Venture Life Science Advisors LLC Unchanged 1,031,160 0 1.13% $8,971,000 2 qtrs
Rock Springs Capital Management LP Added 990,913 +45,600 0.22% $8,621,000 18 qtrs
Alphabet Inc Unchanged 889,979 0 0.25% $7,743,000 18 qtrs
AMERIPRISE FINANCIAL INC Added 586,642 +223,108 < 0.01% $5,104,000 8 qtrs
Artal Group S A Unchanged 500,000 0 0.18% $4,350,000 18 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2022
Filed
May 13, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
60,814
Shared
223
None
11,959

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.